奈玛特韦/利托那韦在慢性肾脏病合并新型冠状病毒感染患者中的应用  

Application of Nirmatrelvir/Ritonavir in Patients with Chronic Kidney Disease and SARS-CoV-2 Infection

作　　者：梁宝贤 逄晓云[2] 谢可炜[3] 车妙琳[3] 王琴[3,4] LIANG Baoxian;PANG Xiaoyun;XIE Kewei;CHE Miaolin;WANG Qin(Department of Pharmacy,the Affiliated Hospital of Youjiang Medical University for Nationalities,Baise 533000,China;Department of Pharmacy,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China;Department of Nephrology,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China;Youth Science and Technology Innovation Studio,School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China)

机构地区：[1]右江民族医学院附属医院药学部,百色533000 [2]上海交通大学医学院附属仁济医院药学部,上海200127 [3]上海交通大学医学院附属仁济医院肾脏科,上海200127 [4]上海交通大学医学院青年科技创新工作室,上海200025

出　　处：《医药导报》2024年第9期1440-1444,共5页Herald of Medicine

基　　金：国家自然科学基金资助项目(82000634);上海市青年科技英才扬帆计划(20YF1425000);中国毒理学会临床毒理专项(CST2019CT308)。

摘　　要：新型冠状病毒(简称“新冠病毒”)感染是一种新型呼吸道传染性疾病。慢性肾脏病患者是新冠病毒感染的高危人群,一旦发生新冠病毒感染其进展为重症甚至死亡的比例远远高于普通人群。奈玛特韦/利托那韦可显著降低新冠病毒感染患者的重症和死亡风险。该文对奈玛特韦/利托那韦在不同慢性肾脏病分期合并新冠病毒感染患者中的给药方案及药物相互作用进行综述,以期为慢性肾脏病患者临床合理用药提供参考。Severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)infection is a new respiratory infectious disease.Patients with chronic kidney disease are at high risk of SARS-CoV-2 infection.Once they develop SARS-CoV-2 infection,the rate of progression to severe illness or even death is much higher than that of the general population.Nirmatrelvir/ritonavir significantly reduce the risk of severe illness and death in patients infected with SARS-CoV-2.In this paper,the dosing regimen and drug interaction of nirmatrelvir/ritonavir in patients with different stages of chronic kidney disease complicated with SARS-CoV-2 infection were reviewed to provide a reference for clinical rational medication for patients with chronic kidney disease.

关 键 词：奈玛特韦/利托那韦 新型冠状病毒感染 慢性肾脏病 透析 药物相互作用 

分 类 号：R978.7[医药卫生—药品] R969.3[医药卫生—药学]